ストックスクリーナーアプリを入手
1.02
0.99%
0.01
前日終値:
$1.01
開ける：
$1.02
24時間の取引高:
400.80K
Relative Volume:
0.69
時価総額：
$45.56M
収益：
$20.60M
当期純損益:
$-8.61M
株価収益率:
-7.386
EPS:
-0.1381
ネットキャッシュフロー:
$-5.28M
1週間 パフォーマンス:
+6.37%
1か月 パフォーマンス:
+18.77%
6か月 パフォーマンス:
+25.55%
1年 パフォーマンス:
+3.34%
1日の値動き範囲:
$1.01
$1.08
1週間の範囲:
$0.92
$1.08
52週間の値動き範囲:
$0.565
$1.31
Scynexis Inc Stock (SCYX) Company Profile
Compare SCYX vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
1.02 | 44.66M | 20.60M | -8.61M | -5.28M | -0.1381 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-01-22 | 開始されました | Guggenheim | Buy |
| 2021-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-11 | アップグレード | Needham | Hold → Buy |
| 2018-06-27 | 開始されました | Maxim Group | Buy |
| 2017-10-24 | 開始されました | Guggenheim | Buy |
| 2017-07-10 | 開始されました | ROTH Capital | Buy |
| 2017-05-09 | ダウングレード | Needham | Buy → Hold |
| 2017-03-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-20 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-07 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 再開されました | Brean Capital | Buy |
| 2016-08-17 | 開始されました | Guggenheim | Buy |
| 2016-08-09 | 繰り返されました | Needham | Buy |
| 2016-08-09 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 開始されました | Brean Capital | Buy |
| 2015-12-29 | 開始されました | WBB Securities | Speculative Buy |
| 2015-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-06-10 | 開始されました | Needham | Buy |
| 2014-05-29 | 開始されました | Canaccord Genuity | Buy |
| 2014-05-29 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Scynexis Inc (SCYX) 最新ニュース
Squadron Capital Management LLC Acquires 7,608,695 Shares in SCY - GuruFocus
Ideas Watch: Is SCYNEXIS Inc benefiting from innovation trendsGap Down & Real-Time Buy Zone Alerts - baoquankhu1.vn
SCYNEXIS INC (NASDAQ:SCYX) Combines Minervini Trend Template with High-Growth Momentum Fundamentals - ChartMill
Aug Patterns: Is SCYNEXIS Inc stock trending bullish2026 Reactions & High Win Rate Trade Tips - baoquankhu1.vn
Squadron Fund holds 9.6% of SCYNEXIS (NASDAQ: SCYX) - Stock Titan
Great Point Partners (SCYX) reports 9.99% ownership, joint filing details - Stock Titan
United StatesMintz Advises On SCYNEXIS’ Up To $92.2 Million Private Placement - Mondaq
Scynexis CEO Angulo Gonzalez buys $100k in shares By Investing.com - Investing.com Australia
Scynexis CEO Angulo Gonzalez buys $100k in shares - Investing.com
SCYNEXIS (SCYX) CEO joins private placement, adds stock and warrants - Stock Titan
SCYNEXIS, Inc. (SCYX) stock price, news, quote and history - Yahoo Finance UK
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD TherapeuticsSlideshow (NASDAQ:SCYX) 2026-04-01 - Seeking Alpha
SCYNEXIS Announces $40 Million Private Placement to Fund SCY-770 Development for Rare Kidney Disease - Minichart
SCYNEXIS raises $40 million in private placement financing By Investing.com - Investing.com South Africa
SCYNEXIS acquires SCY-770 for rare kidney disease treatment By Investing.com - Investing.com South Africa
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease - TipRanks
SCYX Should I Buy - Intellectia AI
SCYNEXIS (SCYX) extends cash runway to 2029 with $40M PIPE and SCY-770 ADPKD deal - Stock Titan
SCYNEXIS Acquires PXL-770 (SCY-770) to Advance Innovative ADPKD Therapy with Phase 2 Trial Planned for 2026 - Minichart
Why did SCYX stock jump 10% in pre-market today? - MSN
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline - TipRanks
SCYNEXIS Raises $40 Million in Strategic Private Placement - TipRanks
SCYX to Acquire Poxel's PXL770, Targeting ADPKD Treatment Market - GuruFocus
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - BioSpace
SCYX: Acquisition of SCY-770 enables rapid entry into rare renal disease with strong clinical and commercial prospects - TradingView
Poxel Sells Kidney‑Disease Drug Candidate to Scynexis for Up to $196 Million - Contract Pharma
SCYNEXIS Acquires Novel AMPK Activator for Polycystic Kidney Disease - National Today
Scynexis (SCYX) Secures Acquisition of Innovative Kidney Disease Treatment - GuruFocus
SCYNEXIS Raises $40M in Private Placement - National Today
SCYNEXIS Inc Corporate Update Call Transcript - GuruFocus
SCYNEXIS Acquires Promising ADPKD Therapy PXL-770 - National Today
Scynexis (SCYX) Secures $40M Through Private Placement Agreement - GuruFocus
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease - marketscreener.com
Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement – SCYX Stock Climbs 2% Pre-Market - Stocktwits
Press Release: Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Moomoo
Scynexis (NASDAQ: SCYX) prices $40M equity private placement with warrants - Stock Titan
Scynexis Acquires Poxel's AMPK Activator Program, Paying $8M Upfront Plus Up To $188M Milestones - TradingView — Track All Markets
SCYNEXIS raises $40 million in private placement financing - Investing.com
SCYNEXIS acquires SCY-770 for rare kidney disease treatment - Investing.com
Scynexis (NASDAQ: SCYX) buys SCY-770 kidney drug for $8M upfront - Stock Titan
SCYNEXIS Announces $40.0 Million Private Placement - The Manila Times
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - The Manila Times
SCYX: Acquisition of SCY-770 targets ADPKD, expanding the rare disease portfolio with a novel therapy - TradingView
SCYNEXIS lands cash to fund rare disease drug work into mid-2029 - Stock Titan
Kidney disease drug with Phase 2 study due this year joins SCYNEXIS - Stock Titan
Form 8-KCurrent report - ADVFN
Scynexis Jumps on SCY-770 Deal — But Volume Tells a Cautious Story - Bitget
SCYNEXIS, Inc. announced that it expects to receive $40.019125 million in funding - marketscreener.com
First Participants Dosed in Phase Trial of SCY-247, Building on Oral Formulation Success - Contagion Live
If You Invested $1,000 in Scynexis (SCYX) - Stock Titan
SCYNEXIS (NASDAQ:SCYX) Rating Lowered to “Hold” at Wall Street Zen - Defense World
Scynexis Inc (SCYX) 財務データ
収益
当期純利益
現金流量
EPS
1.06%
1.05%
大文字化:
|
ボリューム (24 時間):